



Essai Clinique

Généré le 06 mai 2024 à partir de

Titre	Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Protocole ID	EMERGE 402 (JZP712-402)
ClinicalTrials.gov ID	NCT04894591
Type(s) de cancer	Poumon à petites cellules
Phase	Phase IV
Stade	Maladie avancée ou métastatique
Type étude	Autre
Médicament	Zepzelca
Institution	INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUEBEC - UL
Ville	
Investigateur principal	Dre Catherine Labbé
Coordonnateur	Brigitte Fortin 418-656-8711 poste 2639
Statut	Fermé
Date d'activation	26-10-2022
But étude	To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Critères d'éligibilité	<ul style="list-style-type: none">• Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.• Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.• Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Critères d'exclusion	<ul style="list-style-type: none">• Patients who discontinued a prior Zepzelca treatment due to adverse events.• Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.• Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.